Logic Bio

LogicBio is developing its proprietary gene therapy platform in order to provide lifelong cures for serious, early-onset rare diseases by combining the best of gene therapy and gene editing. Its GeneRide™ technology enables nuclease-free and promoterless site-specific integration of a therapeutic gene into the genome, allowing durable gene expression in dividing cells.

biopharmaceuticals
Public (NASDAQ:LOGC)
Visit Website
Additional Portfolio Companies
ABAC Therapeutics
Adicet Bio
ArQule
Cathworks
Camel-IDS
Dynacure
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Entera Bio
Eyevensys
EyeYon
ForSight Vision6 (“V6”)
Horama
Keros Therapeutics
Kite Pharma
Levation Pharma
LogicBio Therapeutics
Metabomed
NovellusDX
Novus Therapeutics
Ocon Medical
Prevail Therapeutics
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
VBI Vaccines
Step Pharma
StimatixGI
Sweetch
TargEDys
UroGen
V-Wave
June 25, 2017